Cargando…

Sodium-Glucose Cotransporter 2 Inhibitors Improve Chronic Diabetic Macular Edema

PURPOSE: Diabetic macular edema (DME) is a vision-threatening condition that develops in diabetic patients. The first-line therapy for DME is intravitreal injections of antivascular endothelial growth factor (anti-VEGF) agents; however, the high frequency of repeat injections, invasiveness of the pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Takatsuna, Yoko, Ishibashi, Ryoichi, Tatsumi, Tomoaki, Koshizaka, Masaya, Baba, Takayuki, Yamamoto, Shuichi, Yokote, Koutaro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7683151/
https://www.ncbi.nlm.nih.gov/pubmed/33274092
http://dx.doi.org/10.1155/2020/8867079
_version_ 1783612817657561088
author Takatsuna, Yoko
Ishibashi, Ryoichi
Tatsumi, Tomoaki
Koshizaka, Masaya
Baba, Takayuki
Yamamoto, Shuichi
Yokote, Koutaro
author_facet Takatsuna, Yoko
Ishibashi, Ryoichi
Tatsumi, Tomoaki
Koshizaka, Masaya
Baba, Takayuki
Yamamoto, Shuichi
Yokote, Koutaro
author_sort Takatsuna, Yoko
collection PubMed
description PURPOSE: Diabetic macular edema (DME) is a vision-threatening condition that develops in diabetic patients. The first-line therapy for DME is intravitreal injections of antivascular endothelial growth factor (anti-VEGF) agents; however, the high frequency of repeat injections, invasiveness of the procedure, and high cost are drawbacks for this treatment. The purpose of this report is to present our findings in 3 patients with chronic DME whose edema was resolved soon after oral doses of sodium-glucose cotransporter-2 (SGLT2) inhibitors were used. Case Presentation. Case 1 was a 66-year-old woman diagnosed with moderate nonproliferative diabetic retinopathy (DR) with DME that had developed a decade earlier. The DME persisted for 4 years in the left eye. The addition of oral empagliflozin, a SGLT2 inhibitor, led to a marked improvement of the DME after one month, and this improvement continued over two years. Case 2 was a 68-year-old woman who was diagnosed with preproliferative DR with bilateral DME. The addition of oral dapagliflozin led to the improvement of the DME after two months, and this improvement continued over one year. Case 3 was a 61-year-old woman who was diagnosed with moderate nonproliferative DR with DME. Oral luseogliflozin was given which led to better glycemic control, and her left central retinal thickness (CRT) was markedly reduced after only two weeks. This reduction was maintained in her left eye for six months without any additional ophthalmic procedures. CONCLUSIONS: Although this study involved only three cases, our findings indicate that SGLT2 inhibitors might have possible efficacy for chronic DME.
format Online
Article
Text
id pubmed-7683151
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-76831512020-12-02 Sodium-Glucose Cotransporter 2 Inhibitors Improve Chronic Diabetic Macular Edema Takatsuna, Yoko Ishibashi, Ryoichi Tatsumi, Tomoaki Koshizaka, Masaya Baba, Takayuki Yamamoto, Shuichi Yokote, Koutaro Case Rep Ophthalmol Med Case Report PURPOSE: Diabetic macular edema (DME) is a vision-threatening condition that develops in diabetic patients. The first-line therapy for DME is intravitreal injections of antivascular endothelial growth factor (anti-VEGF) agents; however, the high frequency of repeat injections, invasiveness of the procedure, and high cost are drawbacks for this treatment. The purpose of this report is to present our findings in 3 patients with chronic DME whose edema was resolved soon after oral doses of sodium-glucose cotransporter-2 (SGLT2) inhibitors were used. Case Presentation. Case 1 was a 66-year-old woman diagnosed with moderate nonproliferative diabetic retinopathy (DR) with DME that had developed a decade earlier. The DME persisted for 4 years in the left eye. The addition of oral empagliflozin, a SGLT2 inhibitor, led to a marked improvement of the DME after one month, and this improvement continued over two years. Case 2 was a 68-year-old woman who was diagnosed with preproliferative DR with bilateral DME. The addition of oral dapagliflozin led to the improvement of the DME after two months, and this improvement continued over one year. Case 3 was a 61-year-old woman who was diagnosed with moderate nonproliferative DR with DME. Oral luseogliflozin was given which led to better glycemic control, and her left central retinal thickness (CRT) was markedly reduced after only two weeks. This reduction was maintained in her left eye for six months without any additional ophthalmic procedures. CONCLUSIONS: Although this study involved only three cases, our findings indicate that SGLT2 inhibitors might have possible efficacy for chronic DME. Hindawi 2020-11-12 /pmc/articles/PMC7683151/ /pubmed/33274092 http://dx.doi.org/10.1155/2020/8867079 Text en Copyright © 2020 Yoko Takatsuna et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Takatsuna, Yoko
Ishibashi, Ryoichi
Tatsumi, Tomoaki
Koshizaka, Masaya
Baba, Takayuki
Yamamoto, Shuichi
Yokote, Koutaro
Sodium-Glucose Cotransporter 2 Inhibitors Improve Chronic Diabetic Macular Edema
title Sodium-Glucose Cotransporter 2 Inhibitors Improve Chronic Diabetic Macular Edema
title_full Sodium-Glucose Cotransporter 2 Inhibitors Improve Chronic Diabetic Macular Edema
title_fullStr Sodium-Glucose Cotransporter 2 Inhibitors Improve Chronic Diabetic Macular Edema
title_full_unstemmed Sodium-Glucose Cotransporter 2 Inhibitors Improve Chronic Diabetic Macular Edema
title_short Sodium-Glucose Cotransporter 2 Inhibitors Improve Chronic Diabetic Macular Edema
title_sort sodium-glucose cotransporter 2 inhibitors improve chronic diabetic macular edema
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7683151/
https://www.ncbi.nlm.nih.gov/pubmed/33274092
http://dx.doi.org/10.1155/2020/8867079
work_keys_str_mv AT takatsunayoko sodiumglucosecotransporter2inhibitorsimprovechronicdiabeticmacularedema
AT ishibashiryoichi sodiumglucosecotransporter2inhibitorsimprovechronicdiabeticmacularedema
AT tatsumitomoaki sodiumglucosecotransporter2inhibitorsimprovechronicdiabeticmacularedema
AT koshizakamasaya sodiumglucosecotransporter2inhibitorsimprovechronicdiabeticmacularedema
AT babatakayuki sodiumglucosecotransporter2inhibitorsimprovechronicdiabeticmacularedema
AT yamamotoshuichi sodiumglucosecotransporter2inhibitorsimprovechronicdiabeticmacularedema
AT yokotekoutaro sodiumglucosecotransporter2inhibitorsimprovechronicdiabeticmacularedema